Mo. Rev. Stat. § 103.190: Lyme disease, coverage for testing, treatment, and management.

1. As used in this section, the terms Lyme disease and posttreatment Lyme disease syndrome shall have the same meaning as given to the terms under section 192.026.

2. The Missouri consolidated health care plan shall, at a minimum, provide coverage for diagnostic testing, treatment, and management of Lyme disease and posttreatment Lyme disease syndrome for participants who receive a diagnosis from a licensed health care provider, acting within the scope of his or her practice, after making a thorough evaluation of the participant's symptoms, diagnostic test results, or response to treatment, including, but not limited to, necessary office visits and ongoing testing. An experimental drug shall be covered as a long-term antibiotic therapy if it is approved for an indication by the U.S. Food and Drug Administration. A drug, including, but not limited to, an experimental drug, shall be covered for an off-label use in the treatment of a tick-borne disease if the drug has been approved by the U.S. Food and Drug Administration.